Stereotactic Body Radiation Therapy (SBRT) has emerged as an exciting and validated treatment option for men with localized prostate cancer. This is due to the unique radiobiology of prostate adenocarcinoma coupled with innovation in treatment delivery. Long-term data continues to emerge demonstrating favorable biochemical control coupled with low normal tissue toxicity. Prostate SBRT is now considered a standard of care option for men with localized prostate cancer

This Comprehensive and Interactive Hands-On Course is designed to provide Radiation Oncologists, Urologists and Medical Oncologists with an overview of the long-term data, treatment planning techniques and clinical considerations for optimizing the use of SBRT while minimizing side effects.

This course will include didactic lectures and hands-on workshops that will involve contouring, treatment planning considerations as well as fiducial and hydrogel marker placement. To promote understanding of the intricacies of treatment, an internationally renowned group of physician scientists has been assembled to lead this discussion

1. Describe indications for SBRT for prostate cancer
2. Describe modifications regarding contours and treatment planning to optimize outcomes
3. Demonstrate competence placing fiducial markers and/or assessing image guidance techniques
4. Characterize the rationale for prostate SBRT and review potential side effects, including their management
5. Review parameters of treatment planning approaches to enhance therapeutic effects
6. Describe the radiobiologic and physics-related rationale for employing stereotactic body radiation therapy for prostate cancer.
7. Analyze appropriate candidates for prostate SBRT as well as expected outcomes related to biochemical control and toxicity
8. Integrate holistic approaches with conventional management of localized disease.
9. Discuss controversies and future directions regarding SBRT for prostate cancer, including sequencing with more conventional therapies and changes in prescribed dose to tumor and normal tissue.

ACCME Accreditation
NYU Winthrop Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians through 3/31/2023. Provider #: 0006392. 

AMA Credit Designation
NYU Winthrop Hospital designates this live activity for a maximum of 12.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.